Oscotec Inc.

Translating science into medicine
회원가입
PRESS
  1. No Image 27Feb
    by

    Oscotec/ADEL Initiates First-in-Human Dosing in Ph1 of Anti-MTBR Tau Antibody ADEL-Y01 In Alzheimer's Disease

  2. No Image 01Jun
    by

    Lazertinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: results from the dose escalation and dose expansion parts of a first-in-human, open-label, multicentre, phase 1-2 study

  3. No Image 01Jun
    by

    IPOs spawn instant billionaires

  4. No Image 01Jun
    by

    More than half of Korean biopharma firms view R&D investments as assets.

  5. No Image 01Jun
    by

    Yuhan ups investment in biotechs for immuno-oncology drug push

  6. No Image 01Jun
    by

    Genosco gears up for IPO

  7. No Image 01Jun
    by

    Lazertinib Shows Promising Antitumor Activity in Patients With EGFR+ NSCLC

  8. No Image 01Jun
    by

    Oscotec`s SYK inhibitor Program Gets Korea Drug Fund Money

  9. No Image 01Jun
    by

    INTERVIEW: Oscotec Lays Out Global Ambitions For RA, Cancer Drugs

  10. No Image 01Jun
    by

    G-749, a novel FLT3 Kinase inhibitor, can overcome drug resistance for the treatment of acute myeloid leukemia.

  11. No Image 01Jun
    by

    "Global Immune Thrombocytopenia (ITP) Market Insights, Epidemiology, and Forecasts, 2017-2028 : Focus on United States, Germany, Spain, Italy, France, and the United Kingdom, and Japan"

  12. No Image 01Jun
    by

    AXL receptor tyrosine kinase as a promising anti-cancer approach: functions, molecular mechanisms and clinical applications

Board Pagination Prev 1 2 3 Next
/ 3
© k2s0o1d6e0s8i2g7n. ALL RIGHTS RESERVED.
서버에 요청 중입니다. 잠시만 기다려 주십시오...